McKesson

A Strategic Alliance of AJMC

May 30, 2020
Debra A. Patt, MD, MPH, MBA, a breast cancer specialist at Texas Oncology is the lead author on the study being presented at ASCO.
April 26, 2020
Site of care made a difference in chemotherapy costs.
March 16, 2020
While the cell and gene therapies approved so far are indicated for rare diseases with small patient populations, the successes of chimeric antigen receptor-T (CAR-T) therapies and expanding interest from biopharma stress the need to rapidly scale the supply chain as these therapies move toward commercial availability for more disease states and larger patient populations.
 
September 17, 2019
As rising drug costs continue to take up a larger portion of the total cost of care, practices in the Oncology Care Model find themselves in control of a shrinking portion of total costs, according to anecdotes from an academic medical center and a community-based practice during the National Comprehensive Cancer Network’s Policy Summit held September 12 in Washington, DC.
September 11, 2019
Nearly 28.5 million Americans are uninsured or underinsured, leaving them at risk for medical costs they may not be able to afford. Surprise billing is particularly problematic for acute, or emergency cases.
August 22, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
August 10, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, explains the impact of lag time between a drug's approval and its availability for use in the electronic medical record (EMR).
July 29, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the lag time between a drug's approval and its availability in the electronic medical record (EMR) for the physician to order.
July 16, 2019
With real-world data, there's an opportunity to take a new agent and see how patients outside that clinical trial would do, explained Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences.
June 23, 2019
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses the need for standardizing the use of real-world evidence for measuring endpoints in clinical practice.
March 07, 2019
McKesson has announced a collaboration with Navigating Cancer to offer a patient relationship management platform for community-based oncologists.
February 23, 2017
The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncology™, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.
January 18, 2017
What we're reading, January 18, 2017: GOP senators plan to reveal Obamacare replacement next week; McKesson to pay $150 million to settle claims that it didn't report suspicious opioid orders; and Sylvia Mathews Burwell will go on DC health insurance exchange once she leaves her post.
November 05, 2016
As the healthcare industry continues its transition towards alternative payment models (APMs), some providers might feel apprehensive about keeping up with new requirements like those in the Medicare Access and CHIP Reauthorization Act (MACRA) final rule. However, these providers can use healthcare information technology (IT), data analysis tools, and other resources to adapt to these changes, according to Suzanne Travis, vice president of regulatory strategy at McKesson.
August 01, 2016
Two consultants who help stakeholders in value-based transitions say CMS is serious about an aggressive pace for payment reform.
July 21, 2016
There are signs that smaller providers, in particular, are not moving toward value-based reimbursement at the same pace as larger healthcare stakeholders.
June 15, 2015
With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood in making treatment decisions. In a special issue on cardio-oncology in Evidence-Based Oncology, a publication of The American Journal of Managed Care, Texas Oncology's Dr. Debra Patt discusses the challenge of translating what is known from clinical trials to real-world patients, who may be older and have more health problems.
February 14, 2014
Oncology clinical pathways have helped health plans deliver quality care while keeping an eye on costs. The lack of standardization in pathways can be cumbersome on a busy oncology practice. If Medicare adopts a pathways model, it could offer a framework for broader use.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.